369 related articles for article (PubMed ID: 33886088)
21. A critique and systematic review of the clinical utility of hepatitis B core-related antigen.
Adraneda C; Tan YC; Yeo EJ; Kew GS; Khakpoor A; Lim SG
J Hepatol; 2023 Apr; 78(4):731-741. PubMed ID: 36586590
[TBL] [Abstract][Full Text] [Related]
22. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review.
Jaroenlapnopparat A; Chayanupatkul M; Tangkijvanich P
J Gastroenterol Hepatol; 2021 Sep; 36(9):2349-2362. PubMed ID: 33811375
[TBL] [Abstract][Full Text] [Related]
23. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
[TBL] [Abstract][Full Text] [Related]
24. Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation.
Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Nan Y; Zheng H; Liu J; Wei L; Feng B
BMC Gastroenterol; 2023 Jun; 23(1):224. PubMed ID: 37386460
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearance.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Saitoh S; Arase Y; Kobayashi M; Kumada H
J Gastroenterol; 2024 Jan; 59(1):34-44. PubMed ID: 37837569
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
[TBL] [Abstract][Full Text] [Related]
27. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk.
Hsu YC; Nguyen MH; Mo LR; Wu MS; Yang TH; Chen CC; Tseng CH; Tai CM; Wu CY; Lin JT; Tanaka Y; Chang CY
Aliment Pharmacol Ther; 2019 Jan; 49(1):107-115. PubMed ID: 30450681
[TBL] [Abstract][Full Text] [Related]
28. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.
Chuaypen N; Posuwan N; Payungporn S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
Liver Int; 2016 Jun; 36(6):827-36. PubMed ID: 26678018
[TBL] [Abstract][Full Text] [Related]
29. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss.
Xue Y; Zhang M; Li T; Liu F; Zhang LX; Fan XP; Yang BH; Wang L
World J Gastroenterol; 2021 Apr; 27(14):1497-1506. PubMed ID: 33911470
[TBL] [Abstract][Full Text] [Related]
30. Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
Wang Y; Liao H; Deng Z; Liu Y; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Duan Z; Lu F; Zheng S
J Viral Hepat; 2022 Jun; 29(6):420-431. PubMed ID: 35274400
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
Jung KS; Park JY; Chon YE; Kim HS; Kang W; Kim BK; Kim SU; Kim do Y; Han KH; Ahn SH
J Gastroenterol; 2016 Aug; 51(8):830-9. PubMed ID: 26687058
[TBL] [Abstract][Full Text] [Related]
32. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
33. IP10 and Anti-HBc can Predict Virological Relapse and HBsAg Loss in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Discontinuation.
Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Nan Y; Zheng H; Liu J; Wei L; Feng B
Dig Dis; 2023; 41(6):922-931. PubMed ID: 37586356
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients.
Li J; Wu Z; Wang GQ; Zhao H
Chin Med J (Engl); 2021 Mar; 134(10):1160-1167. PubMed ID: 33734135
[TBL] [Abstract][Full Text] [Related]
35. Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB.
Wübbolding M; Lopez Alfonso JC; Lin CY; Binder S; Falk C; Debarry J; Gineste P; Kraft ARM; Chien RN; Maasoumy B; Wedemeyer H; Jeng WJ; Meyer Hermann M; Cornberg M; Höner Zu Siederdissen C
Hepatol Commun; 2021 Jan; 5(1):97-111. PubMed ID: 33437904
[TBL] [Abstract][Full Text] [Related]
36. End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients.
Brakenhoff SM; de Knegt RJ; van Campenhout MJH; van der Eijk AA; Brouwer WP; van Bömmel F; Boonstra A; Hansen BE; Berg T; Janssen HLA; de Man RA; Sonneveld MJ
J Microbiol Immunol Infect; 2023 Feb; 56(1):31-39. PubMed ID: 35941076
[TBL] [Abstract][Full Text] [Related]
37. Serum HBV RNA is associated with liver fibrosis regression in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues.
Bian D; Zhao J; Liao H; Wang Y; Ren Y; Jiang Y; Liu S; Chen X; Hu Z; Duan Z; Lu F; Zheng S
J Viral Hepat; 2023 Apr; 30(4):303-309. PubMed ID: 36533536
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B Core-Related Antigen is a Biomarker for off-Treatment Relapse After Long-Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B.
Liao G; Ding X; Xia M; Wu Y; Chen H; Fan R; Zhang X; Cai S; Peng J
Int J Gen Med; 2021; 14():4967-4976. PubMed ID: 34483685
[TBL] [Abstract][Full Text] [Related]
39. Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients.
Zhao J; Bian D; Liao H; Wang Y; Ren Y; Jiang Y; Liu S; Chen X; Hu Z; Duan Z; Lu F; Zheng S
Front Cell Infect Microbiol; 2023; 13():1083912. PubMed ID: 37065191
[TBL] [Abstract][Full Text] [Related]
40. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.
Chi H; Hansen BE; Yim C; Arends P; Abu-Amara M; van der Eijk AA; Feld JJ; de Knegt RJ; Wong DK; Janssen HL
Aliment Pharmacol Ther; 2015 May; 41(9):867-76. PubMed ID: 25752878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
